Targeting immunogenic cell death in cancer
| العنوان: | Targeting immunogenic cell death in cancer |
|---|---|
| المؤلفون: | Stephen W.G. Tait, Asma Ahmed |
| المصدر: | Molecular Oncology |
| بيانات النشر: | Wiley, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | 0301 basic medicine, Cancer Research, T-Lymphocytes, caspase, medicine.medical_treatment, Cell, chemical and pharmacologic phenomena, Immunogenic Cell Death, Review, 03 medical and health sciences, 0302 clinical medicine, Immune system, Cancer immunotherapy, Neoplasms, Genetics, Alarmins, Animals, Humans, cancer, Medicine, DAMPs, business.industry, Immunity, Cancer, interferon, General Medicine, Endoplasmic Reticulum Stress, medicine.disease, Oncolytic virus, cell death, 030104 developmental biology, medicine.anatomical_structure, Cytokine, Oncology, 030220 oncology & carcinogenesis, Cancer cell, Cancer research, Molecular Medicine, Immunogenic cell death, business |
| الوصف: | Immunogenic cell death (ICD) is a form of cell death that can engage immunity. Therapeutic engagement of ICD in cancer may lead to more effective responses by eliciting antitumor immunity. Here, we discuss various modalities of ICD, highlighting our current understanding of the molecular basis of ICD. Finally, we outline the potential and challenge of harnessing ICD in cancer immunotherapy. Immunogenic cell death (ICD) is a type of cancer cell death triggered by certain chemotherapeutic drugs, oncolytic viruses, physicochemical therapies, photodynamic therapy, and radiotherapy. It involves the activation of the immune system against cancer in immunocompetent hosts. ICD comprises the release of damage‐associated molecular patterns (DAMPs) from dying tumor cells that result in the activation of tumor‐specific immune responses, thus eliciting long‐term efficacy of anticancer drugs by combining direct cancer cell killing and antitumor immunity. Remarkably, subcutaneous injection of dying tumor cells undergoing ICD has been shown to provoke anticancer vaccine effects in vivo. DAMPs include the cell surface exposure of calreticulin (CRT) and heat‐shock proteins (HSP70 and HSP90), extracellular release of adenosine triphosphate (ATP), high‐mobility group box‐1 (HMGB1), type I IFNs and members of the IL‐1 cytokine family. In this review, we discuss the cell death modalities connected to ICD, the DAMPs exposed during ICD, and the mechanism by which they activate the immune system. Finally, we discuss the therapeutic potential and challenges of harnessing ICD in cancer immunotherapy. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1574-7891 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::963fea30c0210626670478f6904b8b3dTest https://eprints.gla.ac.uk/226051/1/226051.pdfTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....963fea30c0210626670478f6904b8b3d |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15747891 |
|---|